{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:13:03Z","timestamp":1769112783734,"version":"3.49.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.mayocp.2014.09.006","type":"journal-article","created":{"date-parts":[[2014,11,19]],"date-time":"2014-11-19T01:10:06Z","timestamp":1416359406000},"page":"109-127","source":"Crossref","is-referenced-by-count":41,"title":["Non\u2013anti-infective Effects of Antimicrobials and Their Clinical Applications"],"prefix":"10.1016","volume":"90","author":[{"given":"Sapna P.","family":"Sadarangani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn L.","family":"Estes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Steckelberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.mayocp.2014.09.006_bib1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMp048021","article-title":"Paul Ehrlich\u2019s magic bullets","volume":"350","author":"Schwartz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2014.09.006_bib2","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.rmed.2013.02.009","article-title":"Role of long term antibiotics in chronic respiratory diseases","volume":"107","author":"Babu","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.mayocp.2014.09.006_bib3","doi-asserted-by":"crossref","first-page":"584262","DOI":"10.1155\/2012\/584262","article-title":"Pathogen and host-directed anti-inflammatory activities of macrolide antibiotics","volume":"2012","author":"Steel","year":"2012","journal-title":"Mediators Inflamm"},{"issue":"9","key":"10.1016\/j.mayocp.2014.09.006_bib4","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1365-2222.2012.03979.x","article-title":"Long-term macrolide treatment of chronic inflammatory diseases: risks, benefits and future developments","volume":"42","author":"Cameron","year":"2012","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1517\/14656566.5.3.541","article-title":"Macrolide antibiotics: current and future uses","volume":"5","author":"Labro","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.mayocp.2014.09.006_bib6","doi-asserted-by":"crossref","first-page":"159354","DOI":"10.1155\/2012\/159354","article-title":"Macrolides in chronic inflammatory skin disorders","volume":"2012","author":"Alzolibani","year":"2012","journal-title":"Mediators Inflamm"},{"issue":"4","key":"10.1016\/j.mayocp.2014.09.006_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000185690","article-title":"Treatment of gastroparesis: an update","volume":"78","author":"Gumaste","year":"2008","journal-title":"Digestion"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1345\/aph.1R541","article-title":"Azithromycin for the treatment of gastroparesis","volume":"47","author":"Potter","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.mayocp.2014.09.006_bib9","unstructured":"US Food and Drug Administration. Azithromycin (Zithromax or Zmax): drug safety communication: risk of potentially fatal heart rhythms. http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm343350.htm?source=govdelivery. Published March 12, 2013. Accessed August 28,\u00a02014."},{"issue":"20","key":"10.1016\/j.mayocp.2014.09.006_bib10","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.mayocp.2014.09.006_bib11","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1300799","article-title":"Use of azithromycin and death from cardiovascular causes","volume":"368","author":"Svanstr\u00f6m","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.mayocp.2014.09.006_bib12","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJMp1302726","article-title":"Cardiovascular risks with azithromycin and other anti-bacterial drugs","volume":"368","author":"Mosholder","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S2213-2600(13)70038-9","article-title":"Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases","volume":"1","author":"Serisier","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.rmed.2013.09.014","article-title":"Nontuberculous mycobacterial (NTM) lung disease: the top then essentials","volume":"108","author":"Aksamit","year":"2014","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.mayocp.2014.09.006_bib15","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.mayocp.2014.09.006_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1378\/chest.123.1.261","article-title":"Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases","volume":"123","author":"Garey","year":"2003","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000239440","article-title":"The influence of azithromycin on the biofilm production of Pseudomonas aeruginosa in\u00a0vitro","volume":"42","author":"Ichimiya","year":"1996","journal-title":"Chemotherapy"},{"issue":"6","key":"10.1016\/j.mayocp.2014.09.006_bib18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.pupt.2009.03.002","article-title":"Effects of prolonged used of azithromycin in patients with cystic fibrosis: a meta-analysis","volume":"22","author":"Florescu","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.mayocp.2014.09.006_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1183\/09031936.00042208","article-title":"Long-term macrolide therapy in chronic inflammatory airway diseases","volume":"33","author":"Crosbie","year":"2009","journal-title":"Eur Respir J"},{"issue":"13","key":"10.1016\/j.mayocp.2014.09.006_bib20","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.mayocp.2014.09.006_bib21","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1569-1993(03)00021-3","article-title":"Improved lung function and body mass index associated with long-term use of macrolide antibiotics","volume":"2","author":"Pirzada","year":"2003","journal-title":"J\u00a0Cyst Fibros"},{"issue":"7","key":"10.1016\/j.mayocp.2014.09.006_bib23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ppul.21601","article-title":"Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa","volume":"47","author":"Saiman","year":"2012","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.mayocp.2014.09.006_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1345\/aph.1E282","article-title":"Use of macrolides and tetracyclines for chronic inflammatory diseases","volume":"39","author":"Voils","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"9842","key":"10.1016\/j.mayocp.2014.09.006_bib25","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomized, double-blind, placebo controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.mayocp.2014.09.006_bib26","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.mayocp.2014.09.006_bib27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mayocp.2014.09.006_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pupt.2014.02.002","article-title":"Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials","volume":"29","author":"Zhuo","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1183\/09031936.99.13236199","article-title":"A pilot study of low-dose erythromycin in bronchiectasis","volume":"13","author":"Tsang","year":"1999","journal-title":"Eur Respir R"},{"issue":"5","key":"10.1016\/j.mayocp.2014.09.006_bib30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.healun.2009.12.003","article-title":"Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome","volume":"29","author":"Jain","year":"2010","journal-title":"J.\u00a0Heart Lung Transplant"},{"issue":"8","key":"10.1016\/j.mayocp.2014.09.006_bib31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/ctr.12401","article-title":"Azithromycin improves lung function in patients with post-lung transplant bronchiolitis obliterans syndrome: a meta-analysis","volume":"28","author":"Kingah","year":"2014","journal-title":"Clin Transplant"},{"issue":"6, pt 1","key":"10.1016\/j.mayocp.2014.09.006_bib32","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","article-title":"Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin","volume":"157","author":"Kudoh","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.mayocp.2014.09.006_bib33","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0954-6111(03)00042-8","article-title":"Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis","volume":"97","author":"Kadota","year":"2003","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.mayocp.2014.09.006_bib34","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1517\/14656566.6.10.1681","article-title":"Update on antimicrobial agents: new indications of older agents","volume":"6","author":"Pasquale","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.mayocp.2014.09.006_bib35","first-page":"CD009764","article-title":"Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)","volume":"11","author":"Herath","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.mayocp.2014.09.006_bib36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"15","key":"10.1016\/j.mayocp.2014.09.006_bib37","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa044080","article-title":"The effect of telithromycin in acute exacerbations of asthma","volume":"354","author":"Johnston","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2014.09.006_bib38","first-page":"CD002997","article-title":"Macrolides for chronic asthma","volume":"4","author":"Richeldi","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib39","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-4632.2008.03445.x","article-title":"Comparison of efficacy of azithromycin vs doxycycline in the treatment of rosacea: a randomized open clinical trial","volume":"47","author":"Akyani","year":"2008","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.mayocp.2014.09.006_bib40","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/archderm.140.4.489","article-title":"Oral use of azithromycin for the treatment of acne rosacea","volume":"140","author":"Fernandez-Obregon","year":"2004","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.mayocp.2014.09.006_bib41","first-page":"898","article-title":"Azithromycin as an alternative rosacea therapy when tetracyclines prove problematic","volume":"7","author":"Modi","year":"2008","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2230.2006.02322.x","article-title":"The effect of azithromycin on reactive oxygen species in rosacea","volume":"32","author":"Bakar","year":"2007","journal-title":"Clin Exp Dermatol"},{"issue":"suppl","key":"10.1016\/j.mayocp.2014.09.006_bib43","first-page":"21","article-title":"Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin?","volume":"107","author":"Valdimarsson","year":"1997","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.mayocp.2014.09.006_bib44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1046\/j.1365-2230.2001.00831.x","article-title":"Psoriasis vulgaris: a sterile antibacterial skin reaction mediated by cross-reactive T cells? an immunological view of the pathophysiology of psoriasis","volume":"26","author":"Prinz","year":"2001","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib45","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1684\/ejd.2009.0663","article-title":"High prevalence of Staphylococcus aureus cultivation and superantigen production in patients with psoriasis","volume":"19","author":"Balci","year":"2009","journal-title":"Eur J Dermatol"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1684\/ejd.2010.0930","article-title":"Long term oral azithromycin in chronic plaque psoriasis: a controlled trial","volume":"20","author":"Saxena","year":"2010","journal-title":"Eur J Dermatol"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2230.2007.02370.x","article-title":"Efficacy of erythromycin for psoriasis vulgaris","volume":"32","author":"Polat","year":"2007","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4, guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"13","key":"10.1016\/j.mayocp.2014.09.006_bib49","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/01.CIR.0000012544.07696.1F","article-title":"Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome","volume":"105","author":"Sinisalo","year":"2002","journal-title":"Circulation"},{"issue":"9360","key":"10.1016\/j.mayocp.2014.09.006_bib50","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0140-6736(03)12706-7","article-title":"Effect of short-term treatment with azithromycin on recurrent ischemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomized controlled trial","volume":"361","author":"Cercek","year":"2003","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.mayocp.2014.09.006_bib51","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/jama.290.11.1459","article-title":"Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial","volume":"290","author":"O\u2019Connor","year":"2003","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.mayocp.2014.09.006_bib52","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/01.CIR.99.12.1540","volume":"99","author":"Anderson","year":"1999","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.mayocp.2014.09.006_bib53","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1161\/01.CIR.0000027820.66786.CF","article-title":"Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA)","volume":"106","author":"Stone","year":"2002","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.mayocp.2014.09.006_bib54","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2146\/ajhp060539","article-title":"Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis","volume":"64","author":"Baker","year":"2007","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib55","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/jac\/dkl537","article-title":"The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks","volume":"59","author":"Hawkyard","year":"2007","journal-title":"J\u00a0Antimicrob. Chemother"},{"issue":"5","key":"10.1016\/j.mayocp.2014.09.006_bib56","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2982.2005.00675.x","article-title":"Basic and clinical pharmacology of new motility promoting agents","volume":"17","author":"Galligan","year":"2005","journal-title":"Neurogastroenterol Motil"},{"issue":"6","key":"10.1016\/j.mayocp.2014.09.006_bib57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MCG.0b013e31824e14c1","article-title":"Motility disorders of the upper gastrointestinal tract in the intensive care unit: pathophysiology and contemporary management","volume":"46","author":"Stupak","year":"2012","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.mayocp.2014.09.006_bib58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/0884533609357570","article-title":"Current and future therapeutic prokinetic therapy to improve enteral feed intolerance in the ICU patient","volume":"25","author":"Fraser","year":"2010","journal-title":"Nutr Clin Pract"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib59","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00003246-200002000-00025","article-title":"Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study","volume":"28","author":"MacLaren","year":"2000","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/0148607109335234","article-title":"Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)","volume":"33","author":"McClave","year":"2009","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"1","key":"10.1016\/j.mayocp.2014.09.006_bib61","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/cc3956","article-title":"Erythromycin for prokinesis: imprudent prescribing?","volume":"10","author":"Dall\u2019Antonia","year":"2006","journal-title":"Crit Care"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib62","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clnu.2006.01.021","article-title":"ESPEN Guidelines on Enteral Nutrition: Intensive Care","volume":"25","author":"Kreymann","year":"2006","journal-title":"Clin Nutr"},{"issue":"7-8","key":"10.1016\/j.mayocp.2014.09.006_bib63","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365521.2011.568520","article-title":"Erythromycin prior to endoscopy in acute upper gastrointestinal bleeding: a meta-analysis","volume":"46","author":"Szary","year":"2011","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib64","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.gie.2010.09.043","article-title":"Effect of erythromycin before endoscopy in patients presenting with variceal bleeding: a prospective, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Altraif","year":"2011","journal-title":"Gastrointest Endosc"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib65","first-page":"259","article-title":"Oral erythromycin and symptomatic relief of gastroparesis: a systematic review","volume":"98","author":"Maganti","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib66","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.phrs.2010.10.004","article-title":"Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanism of action","volume":"63","author":"Griffin","year":"2011","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib67","doi-asserted-by":"crossref","first-page":"C539","DOI":"10.1152\/ajpcell.00047.2010","article-title":"Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties: review of the literature","volume":"299","author":"Griffin","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib68","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.12139","article-title":"Minocycline: far beyond an antibiotic","volume":"169","author":"Garrido-Mesa","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.mayocp.2014.09.006_bib69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.phrs.2012.10.006","article-title":"What is beyond the non-antibiotic properties of minocycline?","volume":"67","author":"Garrido-Mesa","year":"2013","journal-title":"Pharmacol Res"},{"issue":"9","key":"10.1016\/j.mayocp.2014.09.006_bib70","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","article-title":"Safety of doxycycline and minocycline: a systematic review","volume":"27","author":"Smith","year":"2005","journal-title":"Clin Ther"},{"issue":"12","key":"10.1016\/j.mayocp.2014.09.006_bib71","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0025-6196(12)62479-3","article-title":"Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole","volume":"66","author":"Smilack","year":"1991","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.mayocp.2014.09.006_bib72","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-4632.2004.02108.x","article-title":"Tetracycline and other tetracycline-derivative straining of the teeth and oral cavity","volume":"43","author":"S\u00e1nchez","year":"2004","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib73","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.phrs.2010.10.007","article-title":"Clinical applications of non-antimicrobial tetracyclines in dermatology","volume":"63","author":"Monk","year":"2011","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.mayocp.2014.09.006_bib74","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archderm.139.4.459","article-title":"Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne","volume":"139","author":"Skidmore","year":"2003","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.mayocp.2014.09.006_bib75","first-page":"1149","article-title":"Subantimicrobial-dose doxycycline in the treatment of moderate facial acne","volume":"7","author":"Toossi","year":"2008","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.mayocp.2014.09.006_bib76","first-page":"CD002086","article-title":"Minocycline for acne vulgaris: efficacy and safety","volume":"8","author":"Garner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2014.09.006_bib77","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2230.2009.03683.x","article-title":"Management of acne vulgaris: an evidence-based update","volume":"35","author":"Ingram","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib78","first-page":"208","article-title":"Efficacy of tetracyclines in the treatment of acne vulgaris: a review","volume":"158","author":"Simonart","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib79","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/11530200-000000000-00000","article-title":"The role of tetracyclines in rosacea","volume":"11","author":"Alikhan","year":"2010","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.mayocp.2014.09.006_bib80","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","article-title":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea","volume":"56","author":"Del Rosso","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.mayocp.2014.09.006_bib81","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2005.04.069","article-title":"A\u00a0randomized double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea","volume":"53","author":"Sanchez","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.mayocp.2014.09.006_bib82","first-page":"641","article-title":"Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, USP monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea","volume":"6","author":"Fowler","year":"2007","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.mayocp.2014.09.006_bib83","first-page":"573","article-title":"Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea","volume":"7","author":"Del Rosso","year":"2008","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.mayocp.2014.09.006_bib84","first-page":"461","article-title":"Treatment options for acne rosacea","volume":"80","author":"Goldgar","year":"2009","journal-title":"Am Fam Physician"},{"issue":"6","key":"10.1016\/j.mayocp.2014.09.006_bib85","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.phrs.2011.06.013","article-title":"The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease","volume":"64","author":"Federici","year":"2011","journal-title":"Pharmacol Res"},{"issue":"6","key":"10.1016\/j.mayocp.2014.09.006_bib86","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/bjo.66.6.386","article-title":"Oxytetracycline in the treatment of ocular rosacea: a double-blind trial","volume":"66","author":"Bartholomew","year":"1982","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.mayocp.2014.09.006_bib87","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bjo.79.1.42","article-title":"Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea","volume":"79","author":"Seal","year":"1995","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.mayocp.2014.09.006_bib88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1997.03890370055009","article-title":"Ocular rosacea: signs, symptoms, and tear studies before and after treatment with doxycycline","volume":"133","author":"Quarterman","year":"1997","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.mayocp.2014.09.006_bib89","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00003226-200401000-00020","article-title":"Oral tetracyclines for ocular rosacea: an evidence-based review of the literature","volume":"23","author":"Stone","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.mayocp.2014.09.006_bib90","series-title":"Blepharitis","author":"Matoba","year":"2003"},{"issue":"6","key":"10.1016\/j.mayocp.2014.09.006_bib91","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.phrs.2011.06.023","article-title":"Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation","volume":"64","author":"Gu","year":"2011","journal-title":"Pharmacol Res"},{"issue":"6879","key":"10.1016\/j.mayocp.2014.09.006_bib92","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/bmj.306.6879.688","article-title":"Dental disease and risk of coronary heart disease and mortality","volume":"306","author":"DeStefano","year":"1993","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.mayocp.2014.09.006_bib93","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/01.ATV.0000121571.78696.dc","article-title":"Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial","volume":"24","author":"Brown","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib94","first-page":"105","article-title":"Non-antimicrobial properties of tetracyclines: dental and medical implications","volume":"50","author":"Rawal","year":"2001","journal-title":"West Indian Med J"},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib95","doi-asserted-by":"crossref","first-page":"262","DOI":"10.14219\/jada.archive.2011.0165","article-title":"The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation: a randomized, double-masked, placebo-controlled clinical trial","volume":"142","author":"Payne","year":"2011","journal-title":"J\u00a0Am Dent Assoc"},{"issue":"6","key":"10.1016\/j.mayocp.2014.09.006_bib96","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/0091270010373929","article-title":"Clinical and biochemical efficacy of minocycline in nonsurgical periodontal therapy: a randomized controlled pilot study","volume":"51","author":"Basegmez","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib97","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/08959374980120010501","article-title":"Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms","volume":"12","author":"Golub","year":"1998","journal-title":"Adv Dent Res"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib98","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2010.10.008","article-title":"Antimicrobial and non-antimicrobial tetracyclines in human cancer trials","volume":"63","author":"Richards","year":"2011","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib99","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.phrs.2010.11.003","article-title":"Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers","volume":"63","author":"Lokeshwar","year":"2011","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.mayocp.2014.09.006_bib100","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1749-6632.1999.tb07760.x","article-title":"CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer","volume":"878","author":"Selzer","year":"1999","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"10.1016\/j.mayocp.2014.09.006_bib101","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2005.04.2614","article-title":"Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi\u2019s sarcoma: an AIDS Malignancy Consortium Study","volume":"24","author":"Dezube","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2014.09.006_bib102","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/art.1780370505","article-title":"Minocycline in active rheumatoid arthritis: a double-blind, placebo controlled trial","volume":"37","author":"Kloppenburg","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mayocp.2014.09.006_bib103","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-122-2-199501150-00001","article-title":"Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial","volume":"122","author":"Tilley","year":"1995","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.mayocp.2014.09.006_bib104","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/art.1780400510","article-title":"Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial","volume":"40","author":"O\u2019Dell","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.mayocp.2014.09.006_bib105","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/1529-0131(200110)44:10<2235::AID-ART385>3.0.CO;2-A","article-title":"Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine","volume":"44","author":"O\u2019Dell","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.mayocp.2014.09.006_bib106","first-page":"2112","article-title":"Should tetracycline treatment be used more extensively for rheumatoid arthritis? metaanalysis demonstrates clinical benefit with reduction in disease activity","volume":"30","author":"Stone","year":"2003","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocp.2014.09.006_bib107","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.phrs.2011.06.010","article-title":"The road forward: the scientific basis for tetracycline treatment of arthritic disorders","volume":"64","author":"Greenwald","year":"2011","journal-title":"Pharmacol Res"},{"issue":"10","key":"10.1016\/j.mayocp.2014.09.006_bib108","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1001\/archinte.1988.00380100131030","article-title":"Sulfamethoxazole-trimethoprim therapy for Wegener\u2019s granulomatosis","volume":"148","author":"Israel","year":"1988","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.mayocp.2014.09.006_bib109","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-106-6-840","article-title":"Wegener granulomatosis and trimethoprim-sulfamethoxazole: complete remission after a twenty-year course","volume":"106","author":"West","year":"1987","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.mayocp.2014.09.006_bib110","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archinte.163.4.402","article-title":"Trimethoprim-sulfamethoxazole revisited","volume":"163","author":"Masters","year":"2003","journal-title":"Arch Intern Med"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2014.09.006_bib111","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1093\/clinids\/9.Supplement_2.S218","article-title":"Use of trimethoprim-sulfamethoxazole in glucose-6-phosphate dehydrogenase-deficient population","volume":"9","author":"Markowitz","year":"1987","journal-title":"Rev Infect Dis"},{"issue":"5","key":"10.1016\/j.mayocp.2014.09.006_bib112","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/qjmed\/90.5.367","article-title":"Infections and Wegener\u2019s granulomatosis: a cause and effect relationship?","volume":"90","author":"George","year":"1997","journal-title":"QJM"},{"issue":"7","key":"10.1016\/j.mayocp.2014.09.006_bib113","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2169\/internalmedicine.40.666","article-title":"Generalized Wegener\u2019s granulomatosis responding to sulfamethoxazole-trimethoprim monotherapy","volume":"40","author":"Ohtake","year":"2001","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.mayocp.2014.09.006_bib114","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0025-6196(12)65279-3","article-title":"Wegener\u2019s granulomatosis: observations on treatment with antimicrobial agents","volume":"60","author":"DeRemee","year":"1985","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.mayocp.2014.09.006_bib115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Dutch Co-Trimoxazole Wegener Study Group. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis","volume":"335","author":"Stegeman","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2014.09.006_bib116","unstructured":"Nizoral (ketoconazole) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; 2014. http:\/\/www.janssen.com.au\/files\/Products\/Nizoral_PI.pdf. Accessed September 10,\u00a02014."},{"issue":"6","key":"10.1016\/j.mayocp.2014.09.006_bib117","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","article-title":"Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)","volume":"22","author":"Small","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2014.09.006_bib118","first-page":"190","article-title":"Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells","volume":"141","author":"Eichenberger","year":"1989","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mayocp.2014.09.006_bib119","unstructured":"US Food and Drug Administration Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm362415.htm. Accessed September 2,\u00a02014."},{"issue":"3","key":"10.1016\/j.mayocp.2014.09.006_bib120","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1188\/06.CJON.361-366","article-title":"Ketoconazole as a secondary hormonal intervention in advanced prostate cancer","volume":"10","author":"Liebertz","year":"2006","journal-title":"Clin J Oncol Nurs"},{"issue":"5","key":"10.1016\/j.mayocp.2014.09.006_bib121","first-page":"17","article-title":"Treatment of progressive metastatic prostate cancer","volume":"7","author":"Dawson","year":"1993","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"10.1016\/j.mayocp.2014.09.006_bib122","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/pros.22765","article-title":"Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel","volume":"74","author":"Peer","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.mayocp.2014.09.006_bib123","doi-asserted-by":"crossref","unstructured":"Basch E, Loblaw DA, Oliver TK, et\u00a0al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline [published online September 8, 2014]. J Clin Oncol. http:\/\/dx.doi.org\/10.1200\/JCO.2013.54.8404.","DOI":"10.1200\/JCO.2013.54.8404"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619614008301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619614008301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:37:30Z","timestamp":1598488650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619614008301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0025619614008301"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2014.09.006","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}